<DOC>
	<DOCNO>NCT02737748</DOCNO>
	<brief_summary>Primary objective : 1 . To evaluate safety TWB-103 split-thickness skin graft donor site wound ( DSW ) Phase I term Incidence treatment-related AEs SAEs ( include infection bleed ) 2 . To evaluate efficacy Phase I+II TWB-103 split-thickness skin graft donor site wound ( DSW ) term The healing time DSW creation 100 % re-epithelialization Secondary objective : 1 . To evaluate efficacy TWB-103 split-thickness skin graft donor site wound ( DSW ) secondary efficacy endpoint 2 . To evaluate safety TWB-103 split-thickness skin graft donor site wound ( DSW ) secondary safety endpoint</brief_summary>
	<brief_title>TWB-103 Adult Patients With Split-Thickness Skin Graft Donor Site Wounds</brief_title>
	<detailed_description />
	<criteria>A patient eligible study follow apply : 1 . Female/male patient , age 2065 year old 2 . Presenting splitthickness skin graft donor site wound minimum size 15 cm2 , minimum width 3 cm approximate thickness 0.38mm . The graft harvest site skin graft previously obtain . 3 . If primary wind result thermal chemical burn , total body surface area say wound must less 15 % . 4 . Females childbearing potential must document negative serum pregnancy test must agree use highly effective contraceptive treatment period 5 . Willing comply study protocol sign Informed Consent Form Any patient meeting exclusion criterion exclude study participation . 1 . Female patient pregnant lactate planning pregnancy study period . 2 . Clinically significant disease condition may compromise graft take and/or donor site healing ( e.g . presence bleed disorder , capillary fragility , venous arterial disorder directly affect donor site treat , know suspected systemic malignancy , human immunodeficiency virus infection , renal liver disease , uncontrolled diabetes mellitus , thrombocytopenia , vasculitis , poor nutritional status ) . 3 . Patients currently receive receive follow treatment within 4 week prior study entry exclude study : 1. systemic , inhale intranasal corticosteroid immunosuppressant agent ; 2. therapeutic dos anticoagulant ( e.g . Plavix , Coumadin , Heparin , low molecular weight Heparin ) preexist medical condition , dose interruption Screening end study period contraindicate . 4 . Autoimmune disease , e.g . lupus erythematosus , multiple sclerosis . 5 . Hematologic disease , malignancy hypoimmunity . 6 . History HIV congenital immunodeficiency . Note : HIV = human immunodeficiency virus 7 . History alcoholism drug abuse . 8 . Have use tobacco product within 1 week prior treatment . 9 . Patients previously treat cellbased product , include autologous tissue treatment site . 10 . Received investigational drug , device biological/bioactive treatment within 30 day prior study entry . 11 . Any clinical condition significant concurrent disease judge investigator complicate evaluation trial treatment . 12 . History sensitivity bovine porcine origin material</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>April 2016</verification_date>
	<keyword>Donor Site Wounds</keyword>
</DOC>